|Post IPO Valuation|
|MAP Pharmaceuticals, 1/2013||$958M|
|Vicept Therapeutics, 7/2011||$275M|
|Serica Technologies, 2/2010|
Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential â€” to see more clearly, move more freely, express themselves more fully.